Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson said it plans to spin out its pharmaceutical business from its consumer products division, which includes products like Baby Powder, Tylenol and Band-Aid bandages.

Johnson & Johnson Shares Jump In Premarket As Firm Plans To Split Into Two Separate Companies

Health-care conglomerate Johnson & Johnson announced plans Friday to split its consumer products business from its pharmaceutical and medical device operations, creating two publicly traded companies. The news sent shares higher in premarket trading.

Johnson & Johnson plans to split into two companies, separating consumer health business

It plans to break itself up into pharmaceutical and consumer products companies.

Johnson & Johnson Stock Jumps on Reports It Plans to Split In Two

Johnson & Johnson plans to break up into two companies, splitting off its consumer health division that sells Band-Aids and Baby Powder from its large pharmaceuticals unit, it said on Friday.

Johnson & Johnson plans to split into two companies

Johnson & Johnson shares JNJ, -0.74% jumped 3.6% in premarket trade Friday, after Chief Executive Alex Gorksy told the Wall Street Journal that the company plans to split into two companies, splitting off the consumer group from the prescription drugs and medical devices business. J&J will separate the consumer business in 18 to 24 months, he said, because its customers and markets have diverged so much from the rest of the business in recent years, including during the pandemic.

J&J plans to split into two public companies and separate consumer and drug businesses

NEW BRUNSWICK, N.J., Nov. 12, 2021 /PRNewswire/ -- Johnson & Johnson (the "Company") (NYSE: JNJ) today announced its intent to separate the Company's Consumer Health business, creating a new publicly traded company.

Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business

European Medicines Agency (EMA) recommended adding transverse myelitis, a rare type of spinal inflammation, as a side-effect of the Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine. Giving updates on the safety of all coronavirus shots, the EMA said it was assessing reports of capillary leak syndrome, a rare blood condition after Moderna Inc's (NASDAQ: MRNA) vaccine.

EU Lists Spinal Cord Inflammation Probable Side Effect Of JNJ's COVID-19 Shot: Reuters

NEW BRUNSWICK, N.J., Nov. 10, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable access to its single-shot COVID-19 vaccine through a novel mechanism – the COVAX Humanitarian Buffer – that will serve to protect the world's most vulnerable people.

Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World's Most Vulnerable People through Novel Humanitarian Buffer

A U.S. bankruptcy judge on Wednesday put a 60-day halt on tens of thousands of legal claims against Johnson & Johnson alleging that its talc-based products cause cancer.

U.S. judge halts Johnson & Johnson talc litigation for 60 days

Oklahoma's Supreme Court struck down a 2019 ruling against Johnson & Johnson (NYSE: JNJ) and overturned a $465 million fine, finding a judge incorrectly interpreted public nuisance laws. The 5-to-1 decision that overturned the $465 million verdict issued by Cleveland County District Judge Thad Balkman in 2019 is a blow to the argument that companies that marketed, sold, and distributed opioids created a public nuisance.

Oklahoma Supreme Court Overturns Opioid Ruling Against Johnson & Johnson

ConocoPhillips

Disney

Home Depot

Procter & Gamble

Thermo Fisher Scientific

UnitedHealth Group

As we move through the fourth quarter, these top defensive stocks look great for portfolio stability and consistent returns long term. The post 7 Defensive Stocks To Add Portfolio Stability in the Fourth Quarter appeared first on InvestorPlace.

7 Defensive Stocks To Add Portfolio Stability in the Fourth Quarter

Bristol-Myers

Pfizer

Now may be a good time to buy these healthcare dividend giants.

3 Rock-Solid Healthcare Dividend Stocks Now on Sale

A U.S. judge is expected to announce on Wednesday whether Johnson & Johnson must continue defending against tens of thousands of claims that its baby powder and other talc-containing products caused mesothelioma and ovarian cancer.

Judge to rule on request to halt Johnson & Johnson talc lawsuits

The drug maker lost the 2019 case after a judge found that it had created a public nuisance by marketing, selling, and distributing opioids---and was consequently culpable for the drug crisis.

J&J Lauds Oklahoma Ruling That Tosses Out $465 Million Opioid Judgment

Oklahoma Supreme Court justices have reversed a district court decision that ordered Johnson & Johnson to pay hundreds of millions to the state for its role in the opioid crisis.

Oklahoma Supreme Court overturns $435 million J&J opioid ruling

Amazon

BioNTech SE

DoorDash

Moderna

Regeneron Pharmaceuticals

AMC Entertainment

Cisco Systems

Zoom Video

More than a year and a half into the Covid-19 pandemic, the world is changing. More people are returning to the office after months of working at home and restaurants have reopened.

10 Stocks Post-Pandemic: What to Consider, Keep and Run From

NEW BRUNSWICK, N.J., Nov. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has provided a $5MM endowment to Research!America to create an annual award to recognize individuals and organizations working to make a profound difference in public health.

Johnson & Johnson Endows Research!America Outstanding Achievement in Public Health Awards

The Oklahoma Supreme Court on Tuesday overturned a $465 million judgment against Johnson & Johnson in a lawsuit by the state alleging the drugmaker fueled the opioid epidemic through the deceptive marketing of painkillers. The court on a 5-1 vote ruled that the state's public nuisance law does not extend to the manufacturing, marketing and sales of.

Oklahoma's top court overturns $465M opioid award against J&J

The Oklahoma Supreme Court on Tuesday overturned a $465 million judgment against Johnson & Johnson in a lawsuit by the state alleging the drugmaker fueled the opioid epidemic through the deceptive marketing of painkillers.

Oklahoma court overturns $465 million opioid award against Johnson & Johnson

Ambev

Becton, Dickinson and Co.

Global Payments

Lockheed Martin

McCormick

Reynolds Consumer Products

Molson Coors Brewing

IMF October Buys: The 13 Stocks Added To My Fund

NVIDIA

Alibaba

JPMorgan Chase & Co

Taiwan Semiconductor Manufacturing

Visa

There are five businesses with $1-trillion market cap. Here are seven stocks that could be next trillion-dollar company to join the club.

7 Stocks to Buy That Could Be the Next Trillion-Dollar Company

Atmos Energy

Colgate-Palmolive

Con Ed

Hormel Foods

Kimberly-Clark

Altria

Novartis

Northwest Natural Gas

The market is up 8% in a few weeks, and the 28% overvalued S&P 500 offers near-zero inflation and risk-adjusted expected returns over the next five years. Fortunately, there are always wonderful blue-chips available at reasonable to attractive prices, even high-yield, low-volatility dividend aristocrats.

News for Johnson & Johnson Stock (JNJ)